Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.

@article{Ferolla2012ShortenedIO,
  title={Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.},
  author={Piero Ferolla and Antongiulio Faggiano and Franco Grimaldi and Diego Ferone and Giovanni Scarpelli and Valeria Ramundo and Richard Severino and Maria Cristina Bellucci and Luigi Camera and Gaetano Lombardi and Gabriella Angeletti and Annamaria Colao},
  journal={Journal of endocrinological investigation},
  year={2012},
  volume={35 3},
  pages={326-31}
}
BACKGROUND In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects. AIM The objective of this study was to evaluate a different schedule of LAR treatment consistent with a shorter interval between administrations (21 days) in WDNET patients with progressive disease at standard-dose interval. SUBJECTS AND METHODS… CONTINUE READING

From This Paper

Topics from this paper.
18 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…